Core Insights - Eastman Kodak Company has expanded its pharmaceuticals portfolio by introducing four new regulated products, including KODAK Phosphate Buffered Saline (PBS) and KODAK Water for Injection (WFI), which are now available for order by U.S. research laboratories and biopharma developers [1][2] Group 1: Product Offerings - The new PBS formulations include low endotoxin and RNase/DNase/Protease-free options, complementing an already shipping standard PBS 1X [2] - The WFI products mark Kodak's first offerings in this category, ensuring lot-traceable products built on rigorous quality processes [2] Group 2: Quality and Manufacturing - Kodak emphasizes the dependability of U.S. manufacturing and the ability to provide customized formulations and volumes to customers [3] - The company has a history of manufacturing unregulated key starting materials for leading U.S. and multinational contract development and manufacturing organizations (CDMOs) [3] Group 3: Sustainability and Compliance - The new cGMP-compliant pharmaceuticals production facility in Rochester, N.Y. incorporates energy-efficient lighting and custom process equipment to reduce greenhouse gas emissions [4] - Kodak is pursuing ISO 13485 certification for medical device quality management systems, further enhancing its commitment to quality [4]